| Literature DB >> 29281666 |
Eleanor L Watts1, Paul N Appleby1, Demetrius Albanes2, Amanda Black2, June M Chan3,4, Chu Chen5, Piera M Cirillo6, Barbara A Cohn6, Michael B Cook2, Jenny L Donovan7, Luigi Ferrucci8, Cedric F Garland9, Graham G Giles10,11, Phyllis J Goodman12, Laurel A Habel13, Christopher A Haiman14, Jeff M P Holly15, Robert N Hoover2, Rudolf Kaaks16, Paul Knekt17, Laurence N Kolonel18, Tatsuhiko Kubo19, Loïc Le Marchand18, Tapio Luostarinen20, Robert J MacInnis10,11, Hanna O Mäenpää21, Satu Männistö17, E Jeffrey Metter22, Roger L Milne10,11, Abraham M Y Nomura23, Steven E Oliver24, J Kellogg Parsons25, Petra H Peeters26,27, Elizabeth A Platz28, Elio Riboli29, Fulvio Ricceri30,31, Sabina Rinaldi32, Harri Rissanen17, Norie Sawada33, Catherine A Schaefer13, Jeannette M Schenk34, Frank Z Stanczyk35, Meir Stampfer36,37, Pär Stattin38, Ulf-Håkan Stenman39, Anne Tjønneland40, Antonia Trichopoulou41,42, Ian M Thompson43, Shoichiro Tsugane33, Lars Vatten44, Alice S Whittemore45,46, Regina G Ziegler2, Naomi E Allen47, Timothy J Key1, Ruth C Travis1.
Abstract
INTRODUCTION: Sex hormones have been implicated in the etiology of a number of diseases. To better understand disease etiology and the mechanisms of disease-risk factor associations, this analysis aimed to investigate the associations of anthropometric, sociodemographic and behavioural factors with a range of circulating sex hormones and sex hormone-binding globulin.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29281666 PMCID: PMC5744924 DOI: 10.1371/journal.pone.0187741
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Assay methods and geometric mean sex hormone and SHBG concentrations.
| Androstenedione (nmol/L) | A-diol-G (nmol/L) | DHEAS (nmol/L) | Testosterone (nmol/L) | DHT (nmol/L) | Estradiol (pmol/L) | Estrone (pmol/L) | SHBG (nmol/L) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Method | CV % | Geometric mean (95% CI) | Method | CV % | Geometric mean (95% CI) | Method | CV % | Geometric mean (95% CI) | Method | CV (%) | Geometric mean (95% CI) | Method | CV % | Geometric mean (95% CI) | Method | CV % | Geometric mean (95% CI) | Method | CV % | Geometric mean (95% CI) | Method | CV % | Geometric mean (95% CI) | ||
| ATBC | E RIA | 7 | 4.7 (4.4–5.0) | E RIA | 12.3 | 5.7 (5.3–6.2) | E RIA | 11.3 | 3069 (2825–3335) | E RIA | 5.5 | 20.5 (19.5–21.5) | E RIA | 8.9 | 1.8 (1.7–2.0) | E RIA | 13.7 | 102 (97–107) | E RIA | 14.1 | 153 (146–159) | IRMA | 4.2 | 85.2 (80.3–90.4) | |
| BLSA | - | - | - | - | - | - | NE RIA | 2–6.6 | 3393 (3006–3830) | NE RIA | 3.3–6.4 | 15.3 (14.2–16.4) | - | - | - | - | - | - | - | - | - | NE RIA | 1.8–22 | 81.1 (74.5–88.3) | |
| CARET | E RIA | 5–9 | 2.7 (2.5–2.8) | NE RIA | 1.5–4.8 | 12.0 (11.3–12.8) | NE RIA | 0.8–1.9 | 1919 (1785–2064) | E RIA | 1–12 | 14.1 (13.5–14.7) | - | - | - | E RIA | 5–13 | 194 (186–201) | - | - | - | IRMA | 2–7 | 27.1 (25.8–28.6) | |
| CHDS | - | - | - | - | - | - | - | - | - | E RIA | 9–11 | 22.0 (21.2–22.8) | - | - | - | E RIA | 8–10 | 162 (156–167) | - | - | - | IA | 4–6 | 32.9 (31.5–34.4) | |
| EPIC | NE RIA | 3.5–11.1 | 4.7 (4.5–4.8) | NE RIA | 4.1–9.9 | 12.9 (12.3–13.5) | - | - | - | NE RIA | 10.8–14.8 | 15.7 (15.3–16.2) | - | - | - | - | - | - | - | - | - | IRMA | 7.7–12.2 | 42.8 (41.2–44.4) | |
| EPIC Norfolk | - | - | - | N/S | 12.1 (11.6–12.6) | N/S | 2378 (2268–2493) | N/S | 15.2 (14.7–15.6) | - | - | - | - | - | - | - | - | - | N/S | 42.0 (40.6–43.5) | |||||
| FMC | NE RIA | 9.5–11.7 | 5.9 (5.6–6.2) | - | - | - | - | - | - | NE RIA | 4.5–7.2 | 22.9 (21.9–23.9) | - | - | - | - | - | - | - | - | - | IMF | 6.6–8.7 | 50.7 (48.1–53.4) | |
| HHS | - | - | - | - | - | - | - | - | - | IMF | 5.5–13 | 19.7 (18.9–20.6) | - | - | - | - | - | - | - | - | - | IMF | 1.3–10.1 | 50.2 (47.6–52.9) | |
| HPFS | - | - | - | NE RIA | 6.7 | 10.7 (10.2–11.2) | - | - | - | ECIA | 4.9 | 15.4 (15.0–15.9) | NE RIA | 9.7 | 1.2 (1.2–1.3) | NE RIA | 5.2 | 111 (108–114) | - | - | - | IRMA | 10.7 | 56.9 (55.0–58.9) | |
| JACC | - | - | - | - | - | - | - | - | - | NE RIA | 5–12 | 15.6 (14.4–16.8) | - | - | - | - | - | - | - | - | - | IRMA | 5.6–6.9 | 43.5 (39.7–47.6) | |
| Janus | - | - | - | - | - | - | - | - | - | E RIA | 5–15 | 22.4 (21.9–22.9) | - | - | - | - | - | - | - | - | - | Precipitation | 5–15 | 49.5 (48.2–50.8) | |
| JHCS 1988 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | E RIA | 9–15 | 66 (62–71) | E RIA | 9–15 | 109 (102–116) | Precipitation | 5–15 | 37.1 (33.9–40.6) | |
| JHCS 1996 | E RIA | 5–15 | 4.9 (4.5–5.3) | E RIA | 5–15 | 9.0 (8.1–9.9) | - | - | - | E RIA | 5–15 | 17.4 (16.3–18.6) | E RIA | 5–15 | 1.8 (1.6–2.0) | - | - | - | - | - | - | - | - | - | |
| JPHC | - | - | - | - | - | - | - | - | - | ECIA | 1–3 | 15.7 (15.1–16.3) | - | - | - | - | - | - | - | - | - | IRMA | 2–8 | 47.5 (45.4–49.7) | |
| KPMCP | - | - | - | - | - | - | NE RIA | N/S | 2467 (2263–2690) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| MCCS | NE RIA | 3.3 | 3.6 (3.5–3.7) | NE RIA | 4.3 | 13.8 (13.3–14.3) | CIA | 12.4 | 2812 (2704–2924) | ECIA | 1.6 | 15.4 (15.0–15.8) | - | - | - | ECIA | 11.1 | 107 (105–109) | - | - | - | IA | 6 | 36.6 (35.6–37.6) | |
| MEC | - | - | - | NE RIA | 3.4 | 9.5 (9.2–9.9) | - | - | - | E RIA | 3.5 | 18.3 (17.8–18.7) | E RIA | 3.8 | 1.9 (1.9–2.0) | - | - | - | - | - | - | ECIA | 3 | 35.9 (34.9–37.0) | |
| MMAS | E RIA | 8.6–10 | 2.9 (2.8–3.0) | - | - | - | NE RIA | 4.1–8.9 | 5375 (5116–5647) | E RIA | 4.6–7.2 | 16.4 (15.9–16.9) | NE RIA | 10.9–12.2 | 0.7 (0.7–0.8) | NE RIA | 3.6–7.1 | 140 (136–143) | - | - | - | Filtration assay | 8–10.9 | 30.4 (29.4–31.5) | |
| NSHDC androg | - | - | - | N/S | 11.7 (11.1–12.4) | - | - | - | N/S | 19.6 (18.9–20.4) | - | - | - | - | - | - | - | - | - | IRMA | N/S | 41.1 (39.2–43.1) | |||
| NSHDC E2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | N/S | - | 77 (74–79) | - | - | - | - | - | - | |
| PCPT | E RIA | 6.9–8.6 | 2.0 (1.9–2.1) | NE RIA | 2.7–14.0 | 12.0 (11.6–12.4) | - | - | - | ECIA | 7.6–11.9 | 12.4 (12.2–12.7) | - | - | - | E RIA | 10–14.9 | 118 (116–121) | E RIA | 9–15.2 | 158 (155–161) | ECIA | 5.2–12.2 | 36.6 (35.6–37.6) | |
| PHS | - | - | - | NE RIA | 7.6 | 13.5 (12.7–14.3) | - | - | - | NE RIA | 8.7 | 16.0 (15.4–16.6) | E RIA | 5.3 | 1.2 (1.1–1.3) | - | - | - | E RIA | 10 | 122 (118–126) | IRMA | 8.9 | 20.6 (19.6–21.6) | |
| PLCO | NE RIA | 14 | 4.1 (4.0–4.2) | NE RIA | 11 | 14.2 (13.7–14.8) | - | - | - | NE RIA | 14 | 15.9 (15.5–16.3) | - | - | - | - | - | - | - | - | - | IRMA | 18 | 43.9 (42.6–45.2) | |
| ProtecT | - | - | - | - | - | - | - | - | - | EIA | N/S | 13.9 (13.4–14.3) | - | - | - | - | - | - | - | - | - | EIA | - | 37.2 (35.8–38.7) | |
| RBS | - | - | - | - | - | - | NE RIA | 3.1–7.3 | 2054 (1910–2208) | E RIA | 4.1–10 | 10.4 (9.9–10.8) | E RIA | 7.5 | 1.4 (1.3–1.5) | E RIA | 8–12 | 72 (70–75) | - | - | - | - | - | - | |
Abbreviations: A-diol-G = Androstanediol glucuronide; ATBC = The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA = The Baltimore Longitudinal Study of Aging; CARET = The Carotene and Retinol Efficacy Trial; CHDS = Child Health and Development Studies; CI = confidence interval; CIA = competitive immunoassay; CV = coefficient of variation; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; E RIA = extraction radioimmunoassay; ECIA = electrochemiluminescence immunoassay; EIA = enzyme immunoassay; EPIC = European Prospective Investigation into Cancer and Nutrition; FMC = Finnish Mobile Clinic Health Examination Survey; HHS = Helsinki Heart Study; HPFS = Health Professionals Follow-Up Study; IA = immunoassay; IMF = immunofluorometry; IRMA = immunoradiometric assay; JACC = Japan Collaborative Cohort Study; JPHC = Japan Public Health Center-based Prospective Study; JHCS = Japan-Hawaii Cancer Study; KPMCP = Kaiser Permanente Medical Care Program; MCCS = Melbourne Collaborative Cohort Study; MEC = Multiethnic Cohort Study of Diet and Cancer; MMAS = Massachusetts Male Aging Study; NE RIA = non-extraction radioimmunoassay; NSHDC = Northern Sweden Health and Disease Cohort (androg = androgens; E2 = estradiol); PCPT = Prostate Cancer Prevention Trial; PHS = Physicians' Health Study; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; ProtecT = Prostate Testing for Cancer and Treatment; RBS = Rancho Bernardo Study; SHBG = Sex hormone binding globulin
†Intra-assay.
a Inter-assay.
‡Intra-and inter-assay range.
b Not specified.
Participant characteristics by study.
| Study, country | N (% of total) | Mean age, years (SD) | Age range, years | Year of birth | Mean height, cm (SD) | Mean BMI, kg/m2 (SD) | % Current drinkers (median daily alcohol consumption, g alcohol) | % Current smokers (median number of daily cigarettes) | % White ethnic group | % Married/ cohabiting at blood collection | % University degree | % Family history of prostate cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATBC, Finland | 231 (1.9%) | 60.5 (5.2) | 50–69 | 1915–1936 | 173.8 (6.8) | 25.9 (3.7) | 85.4 (8.5) | 100 (20) | - | 82.3 | 5.6 | 2.5 |
| BLSA, USA | 112 (0.9%) | 56.4 (12.8) | 30–84 | 1895–1948 | 176.8 (6.0) | 25.7 (3.0) | - | 21.4 | 95.5 | 91.8 | 57.1 | - |
| CARET, USA | 300 (2.5%) | 62.8 (6.0) | 47–77 | 1913–1945 | 174.9 (7.6) | 27.7 (4.4) | 68.2 (5) | 50.0 (20) | 93.7 | 85.9 | 24.2 | 3.3 |
| CHDS, USA | 396 (2.4%) | 34.9 (3.2) | 25–50 | 1912–1941 | 178.7 (6.8) | 24.7 (2.7) | 77.5 (6) | 50.6 (20) | 63.1 | 99.7 | 34.5 | - |
| EPIC, Europe | 638 (5.2%) | 60.9 (6.2) | 43–76 | 1918–1952 | 172.6 (7.0) | 27.0 (3.6) | 87.1 (13) | 27.8 (15) | 100 | 89.1 | 22.9 | - |
| EPIC Norfolk, Europe | 707 (5.7%) | 66.7 (6.5) | 45–78 | 1918–1950 | 172.9 (6.4) | 26.6 (3.2) | 73.8 (8) | 9.3 | 99.9 | 88.3 | 12.5 | 1.7 |
| FMC, Finland | 298 (2.4%) | 57.9 (9.9) | 33–80 | 1890–1937 | 169.6 (6.8) | 26.1 (3.5) | - | 34.2 (15) | 100 | 85.2 | - | - |
| HHS, Finland | 291 (2.4%) | 51.0 (3.8) | 40–56 | 1924–1940 | 174.2 (6.2) | 26.4 (3.1) | - | - | - | - | - | - |
| HPFS, USA | 682 (5.5%) | 65.1 (7.4) | 46–80 | 1913–1946 | 178.1 (6.4) | 26.0 (3.5) | 73.5 (6) | 3.9 (20) | 99.4 | 93.0 | 100 | 10.3 |
| JACC, Japan | 97 (0.8%) | 67.8 (5.8) | 58–83 | 1904–1934 | 159.5 (7.1) | 22.4 (2.7) | 52.6 (2) | 37.2 (20) | 0 | 93.8 | 2.7 | - |
| Janus, Norway | 1,153 (9.4%) | 46.4 (4.2) | 33–63 | 1910–1947 | 176.2 (6.8) | 25.1 (3.2) | - | 62.5 (12) | 100 | - | - | - |
| JHCS 1988, Japanese in Hawaii | 98 (0.8%) | 63.4 (5.6) | 52–74 | 1900–1919 | 162.2 (5.4) | 23.1 (2.8) | 74.5 (5.5) | 36.7 (20) | 0 | 90.8 | 8.2 | - |
| JHCS 1996, Japanese in Hawaii | 139 (1.1%) | 61.9 (5.7) | 52–74 | 1900–1919 | 162.8 (6.4) | 23.2 (2.8) | 78.4 (5) | 28.1 (20) | 0 | 94.2 | 10.1 | - |
| JPHC, Japan | 399 (3.2%) | 59.1 (6.6) | 41–71 | 1923–1949 | 162.0 (6.4) | 23.3 (2.6) | 71.2 (23) | 40.6 (20) | 0 | 91.0 | - | - |
| KPMCP, USA | 212 (1.7%) | 71.8 (4.5) | 60–85 | 1882–1906 | 169.9 (6.7) | 25.8 (3.1) | 69.7 (10) | 17.9 (30) | 98.6 | 82.7 | 5.4 | - |
| MCCS, Australia | 1,058 (8.6%) | 58.3 (7.2) | 40–72 | 1918–1954 | 172.2 (7.3) | 27.2 (3.7) | 78.3 (13) | 13.0 (20) | 100 | 81.0 | 22.2 | - |
| MEC, USA | 922 (7.5%) | 68.7 (7.2) | 48–84 | 1918–1948 | 174.2 (7.7) | 27.1 (4.2) | 90.9 (9) | 12.6 (15) | 13.2 | 78.1 | 32.2 | 9.0 |
| MMAS, USA | 651 (5.3%) | 57.6 (7.0) | 41–70 | 1916–1946 | 175.8 (7.2) | 27.5 (4.5) | - | 23.5 | 98.8 | 77.1 | 37.8 | - |
| NSHDC E2, Sweden | 465 (3.8%) | 57.6 (4.0) | 40–61 | 1927–1948 | 175.8 (5.9) | 26.6 (3.5) | - | 21.3 | 100 | - | - | - |
| NSHDC androg, Sweden | 382 (3.1%) | 57.2 (4.5) | 39–61 | 1927–1958 | 175.8 (6.2) | 26.5 (3.4) | 100.0 (4) | 17.4 | 100 | 85.6 | 12.4 | |
| PCPT, USA and Canada | 1,025 (8.3%) | 63.3 (5.5) | 55–83 | 1911–1940 | 177.4 (7.0) | 27.7 (4.0) | 68.9 (3) | 7.6 (20) | 83.9 | 87.7 | 37.1 | 20.7 |
| PHS, USA | 376 (3.0%) | 61.3 (7.5) | 41–77 | 1905–1941 | 177.9 (7.0) | 24.6 (2.5) | 84.4 (5) | 8.5 (20) | 96.5 | - | 100 | - |
| PLCO, USA | 858 (7.0%) | 64.8 (4.8) | 54–75 | 1919–1944 | 177.9 (6.5) | 27.4 (3.9) | 70.0 (4) | 9.1 (20) | 100 | 86.9 | 42.2 | 6.1 |
| ProtecT, UK | 539 (4.4%) | 61.5 (5.1) | 50–70 | 1930–1949 | 175.2 (6.5) | 26.6 (3.5) | 84.9 (18) | 10.5 | - | - | - | 4.1 |
| RBS, USA | 301 (2.4%) | 69.4 (9.0) | 47–85 | 1898–1938 | 174.4 (6.8) | 26.0 (3.6) | 68.8 (10) | 7.3 (20) | 100 | 90.4 | 22.6 | - |
| Missing data (%) | - | - | - | - | - | - | 31.1 | 12.2 | 9.0 | 26.3 | 27.3 | 55.5 |
| Overall | 12,330 | 59.9 (9.9) | 25–85 | 1882–1958 | 174.4 (7.8) | 26.4 (3.8) | 77.1 (8) | 23.7 (20) | 89.4 | 86.5 | 35.8 | 8.2 |
Abbreviations: ATBC = The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BLSA = The Baltimore Longitudinal Study of Aging; BMI = body mass index; CARET = The Carotene and Retinol Efficacy Trial; CDHS = Child Health and Development Studies; EPIC = European Prospective Investigation into Cancer and Nutrition; FMC = Finnish Mobile Clinic Health Examination Survey; HHS = Helsinki Heart Study; HPFS = Health Professionals Follow-Up Study; JACC = Japan Collaborative Cohort Study; JPHC = Japan Public Health Center-based Prospective Study; JHCS = Japan-Hawaii Cancer Study; KPMCP = Kaiser Permanente Medical Care Program; MCCS = Melbourne Collaborative Cohort Study; MEC = Multiethnic Cohort; MMAS = Massachusetts Male Aging Study; NSHDC = Northern Sweden Health and Disease Cohort (androg = androgens; E2 = estradiol); PCPT = Prostate Cancer Prevention Trial; PHS = Physicians' Health Study; PLCO Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; ProtecT = Prostate Testing for Cancer and Treatment; RBS = Ranch Bernardo Study; SD = standard deviation
Partial correlation coefficients in control subjects between log-transformed concentrations of sex hormones and SHBG.
| Androstenedione | A-diol-G | DHEAS | Testosterone | Free testosterone | DHT | Estradiol | Free estradiol | Estrone | SHBG | |
|---|---|---|---|---|---|---|---|---|---|---|
| Androstenedione | 1 | |||||||||
| A-diol-G | 0.23 | 1 | ||||||||
| DHEAS | 0.40 | 0.21 | 1 | |||||||
| Testosterone | 0.29 | 0.25 | 0.07 | 1 | ||||||
| Free testosterone | 0.29 | 0.28 | 0.15 | 0.77 | 1 | |||||
| DHT | 0.20 | 0.22 | 0.03 | 0.54 | 0.34 | 1 | ||||
| Estradiol | 0.13 | 0.14 | 0.06 | 0.33 | 0.34 | 0.19 | 1 | |||
| Free estradiol | 0.09 | 0.13 | 0.11 | 0.05 | 0.37 | -0.03 | 0.88 | 1 | ||
| Estrone | 0.45 | 0.18 | 0.15 | 0.27 | 0.26 | 0.19 | 0.54 | 0.50 | 1 | |
| SHBG | 0.10 | 0.04 | -0.08 | 0.52 | -0.11 | 0.36 | 0.10 | -0.36 | 0.09 | 1 |
Measurements are standardised by study and adjusted by age and BMI.
*P<0.01.
Abbreviations: A-diol-G = Androstanediol glucuronide; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 1Relative geometric mean concentrations* of male sex hormones by age category.
*relative to 50–54 years, adjusted for study and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 2Relative geometric mean concentrations* of male sex hormones by BMI category.
*relative to BMI 20.0–22.4 kg/m2, adjusted for study and age. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 3Relative geometric mean concentrations* of male sex hormones by height categories.
*relative to 175.0–179.9 cm, adjusted for study, age and BMI. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 4Relative geometric mean concentrations* of male sex hormones by smoking status.
*relative to never smokers, adjusted for study, age, BMI and alcohol consumption. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 5Relative geometric mean concentrations* of male sex hormones by alcohol consumption categories.
*relative to non-drinkers, adjusted for study, age, BMI and smoking status. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 6Relative geometric mean concentrations* of male sex hormones by ethnic/racial group.
*relative to whites, adjusted for study, age and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 7Relative geometric mean concentrations* of male sex hormones by time of blood collection.
*relative to before 09:00, adjusted for study, age and BMI. #significant interaction with study P<0.01. Abbreviations: A-diol-G = Androstanediol glucuronide; CI = confidence interval; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; SHBG = sex hormone-binding globulin.
Fig 8Simplified schematic of the biosynthesis pathway of sex hormones.
Abbreviations: A-diol-G = Androstanediol glucuronide; DHEAS = Dehydroepiandrosterone sulfate; DHT = Dihydrotestosterone; HSD = Hydroxysteroid dehydrogenase; HST = Hydroxysteroid sulfotransferase; UGT = Uridine 5'-diphospho-glucuronosyltransferase.